EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study

Rivka Friedland, Mirit Glick, Iris Amitay-Laish, Helen Toledano

Dermatology · 2024

DOI: 10.1159/000539374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, 2024. Verfasst von Rivka Friedland und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Unit, Schneider Children's Medical Center, Petah Tiqva, Israel. Hauptthemen laut MEDLINE: Drug Eruptions, Protein Kinase Inhibitors, Proto-Oncogene Mas. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors are in use for several indications for adults and children. Cutaneous toxicities are among the most common adverse effects. We aimed to describe the spectrum of cutaneous adverse events, its frequency, and severity in a cohort of pediatric patients.

Methods

We reviewed all records of patients in our tertiary treatment center treated with MEK inhibitors between January 2016 and January 2023 for all indications.

Results

Among 33 patients, 76% reported cutaneous adverse effects. The highest prevalence was in the group of patients treated with trametinib (90%), followed by the group treated with selumetinib (50%) and the group treated with a combination of trametinib and B-Raf proto-oncogene serine/threonine-protein kinase inhibitor (dabrafenib, 34%). Xerosis, dermatitis, paronychia, and hair heterochromia were most frequently reported. Severity was graded 1 or 2 for most adverse events, and 237 visits to the dermatology clinic related to these adverse events were recorded.

Conclusions

Cutaneous adverse events are common in the pediatric population as in adults, but the clinical spectrum is different. Although considered mild, multiple dermatological consultations reflect the distress caused by these events. Dermatologists have a central role in the multidisciplinary care of pediatric patients receiving these agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug EruptionsProtein Kinase InhibitorsProto-Oncogene MasHumansRetrospective StudiesMaleFemaleChildAdolescentChild, PreschoolPyridonesPyrimidinonesInfantSeverity of Illness IndexImidazolesOximesBenzimidazolesParonychia

Stichwörter der Autor:innen

Adverse drug reactionChildMedical oncology

Substanzen

Protein Kinase InhibitorsProto-Oncogene MastrametinibMAS1 protein, humanPyridonesPyrimidinonesdabrafenibImidazolesOximesAZD 6244

Autor:innen und Institutionen

  • Pediatric Dermatology Unit, Schneider Children's Medical Center, Petah Tiqva, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Division of Dermatology, Rabin Medical Center, Petah Tiqva, Israel.
  • Department of Hematology-Oncology, Schneider Children's Medical Center, Petah Tiqva, Israel.

Zitieren

APA

Friedland, R., Glick, M., Amitay-Laish, I., & Toledano, H. (2024). Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study. Dermatology. https://doi.org/10.1159/000539374

Vancouver

Friedland R, Glick M, Amitay-Laish I, Toledano H. Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study. Dermatology. 2024. doi:10.1159/000539374

BibTeX
@article{Friedland2024,
  author = {Friedland, Rivka and Glick, Mirit and Amitay-Laish, Iris and Toledano, Helen},
  title = {Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study},
  journal = {Dermatology},
  year = {2024},
  doi = {10.1159/000539374}
}
Kostenlos starten →